On Tuesday, Shares of Kohl’s Corporation (NYSE:KSS), gained 3.68% to $45.60.
Kohl’s, declared its Best Black Friday Ever event, inspiring customers with incredible savings on the most sought-after, must-have gifts of the season. The excitement kicks off at Kohl’s stores nationwide with exclusive Black Friday deals and Door busters starting at 6 p.m.on November 26. Kohl’s will offer a faster, more convenient Black Friday shopping experience than ever before and will deliver personalized and engaging touch points in stores and across all devices. For the first time ever, customers eager to get a jumpstart on their shopping lists can start taking advantage of Kohl’s One Day Only Black Friday Deals on Kohls.com!
Kohl’s Corporation operates department stores in the United States. It offers private label, exclusive, and national brand apparel, footwear, accessories, beauty, and home products to children, men, and women customers.
Shares of Merck & Co., Inc. (NYSE:MRK), inclined 0.35% to $54.43, during its last trading session.
Merck, issued the following statement after the conclusion of a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss BRIDION® (sugammadex). BRIDION is the projected trade name for Merck’s investigational agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium.
“We believe that BRIDION has the potential to offer anesthesia professionals an important new option to reverse neuromuscular blockade in the surgical setting,” said Dr. David Michelson, head of global clinical development for neuroscience, Merck Research Laboratories. “Recently’s negotiation is one step in the regulatory process, and we look forward to working with the FDA as it completes the review of our New Drug Application for BRIDION.”
The FDA is not bound by the committee’s guidance but takes its advice into consideration when reviewing investigational medicines. The Prescription Drug User Fee Act (PDUFA) action date for the FDA’s review of BRIDION is Dec. 19, 2015.
If approved, BRIDION would be the first in a new class of medicines, known as selective relaxant binding agents, to be used in the U.S.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Finally, Shares of Scientific Games Corp (NASDAQ:SGMS), ended its last trade with -15.90% loss, and closed at $9.73.
Scientific Games Corporation, stated results for the third quarter ended September 30, 2015.
Gavin Isaacs, Scientific Games’ President and Chief Executive Officer, said, “With an expanding portfolio of innovative new products, systems and services ahead of us, and the heavy lifting of integration mostly behind us, our team successfully accomplished in just eight months what we had originally predictable to achieve in a year. The combined power of our talented people, innovation-focused culture and multiple brands was clearly demonstrated at the recent Global Gaming Expo (“G2E™”) and National Association of State and Provincial Lotteries (“NASPL”) trade shows. At both events, customer feedback to our latest innovative solutions was highly favorable. We have clearly established a solid foundation built on the most extensive portfolio of leading brands and products – counting a diverse revenue base that is more than 60% recurring in nature – targeted at generating consistent long-term profitable growth.”
“The benefit from having accelerated our integration activities yielded savings that contributed to the 850 basis point improvement in AEBITDA margin over the preceding-year period, and enabled us to pay down $73 million of debt in the third quarter, bringing total debt payments for the first nine months of 2015 to $109 million. With the integration largely complete, a deep portfolio of innovative solutions across our businesses and the scale to provide high levels of customer service, our planned priority remain focused on leveraging our capabilities to support customers’ growth while improving our operating metrics,” Mr. Isaacs concluded.
Scientific Games Corporation develops technology-based products and services, and associated content for the gaming and lottery industries worldwide. The company operates through three segments: Gaming, Lottery, and Interactive.